Efficacy of Topical Tretinoin and Topical Minoxidil Cotherapy in Androgenetic Alopecia: A Review

Abstract

Background

Androgenetic alopecia (AGA) frequently occurs in both men and women and is associated with a significant quality-of-life impairment. Topical minoxidil has been demonstrated to have a variable clinical response, and the proposed efficacy of using concomitant topical tretinoin largely stems from increased minoxidil penetration and activation by the follicular sulfotransferase enzyme.

Summary

This review summarizes mechanisms, safety, outcomes, and social media perspectives on the subject. Pharmacokinetic evidence demonstrates a nearly threefold increase in systemic absorption when tretinoin cream is applied before minoxidil, with researchers hypothesizing increased permeability as the cause. However, clinical data regarding combination therapy are minimal. One randomized controlled trial reported similar outcomes between dual therapy and topical minoxidil monotherapy; results from smaller investigations, however, are consistent with the potential conversion of some minoxidil nonresponders to responders when tretinoin is used. A social media analysis of 71 online posts was notable for frequently positive claims regarding the interaction, but tolerability concerns were common.

Key Messages

Though current evidence does not support the first-line use of dual therapy, topical tretinoin may be considered as an adjunct in AGA, especially in patients without response to topical minoxidil. Any potential benefit, however, should be weighed against the potential for increased irritation.

Introduction

Androgenetic alopecia (AGA) is the most common cause of hair loss; it frequently occurs in both men and women, with prevalence increasing by age [1]. In men, the frontal-temporal scalp is often affected with recession and associated vertex thinning, which can progress to partial or complete baldness [2]. In women, it is also referred to as female pattern hair loss and presents with diffuse hair thinning over the frontal and vertex scalp, often with widening of the central part [3]. In both sexes, AGA is associated with a significant health-related quality of life impairment [4].

Topical minoxidil is Federal Drug Administration (FDA)-approved and has long been used for the treatment of men and women with AGA [5, 6]. However, the treatment has a variable clinical response, and a subset of patients may not respond at all [5, 7, 8]. Patient adherence, application technique, dosing frequency, and medication vehicle all may contribute to the lack of success with this subpopulation, and research has additionally implicated the role of altered minoxidil metabolism, including by follicular sulfotransferase enzymes [5, 7]. As systemic therapies are sometimes associated with an increased risk of side effects, oral medication options, including minoxidil, finasteride, and spironolactone, may not be suitable for all patients [6, 9]. Thus, there is an unmet need for strategies to overcome suboptimal response to topical minoxidil [9–11].

One strategy that emerged in efforts to increase the efficacy of topical minoxidil is the concomitant use of topical tretinoin [12]. Although it is not widely considered as a first-line therapy, tretinoin is occasionally used off-label in the treatment of AGA [13]. Increased penetration and elevated follicular sulfotransferase activity have formed the basis of a potential synergistic effect [10, 14]; however, evidence is mixed as to whether topical minoxidil is more effective when used with topical tretinoin [12, 15]. Accordingly, this narrative review focuses on tretinoin-minoxidil combinations to summarize mechanisms, literature regarding safety and outcomes, and social media perspectives on the subject.

We conducted a literature review to summarize the available literature regarding the relative effect of topical Tretinoin on the efficacy of topical and oral Minoxidil. Relevant articles were identified in PubMed, Google Scholar, and Scopus, using various combinations of keywords, including “topical tretinoin,” “topical minoxidil,” “minoxidil and tretinoin,” “hair loss,” and “androgenetic alopecia.”

Additionally, we conducted a review of high-impact social media posts regarding topical tretinoin and topical minoxidil. We selected posts from Google, Instagram, TikTok, and Reddit based on predefined criteria using likes, views, comments, and rankings, and evaluated each for comments on efficacy and tolerability, while also recording creator characteristics. A maximum of 20 were evaluated per platform. Posts that referenced both topical minoxidil and topical tretinoin were identified using the search terms “topical tretinoin hair loss,” “topical tretinoin and minoxidil,” and “tretinoin minoxidil hair loss.” Rstudio was used for demographic statistics and comparison of posts made by physicians (MD posts) with those created by nonphysicians (non-MD posts). With 24 two-sided Fisher’s exact or chi-square tests, a Bonferroni correction was applied, and an adjusted α of 0.002 was used for significance assessment.

Pathophysiology of AGA

Hair grows in follicular units of 1–5 hairs and follows a cyclical growth phase, including anagen (growth), catagen (regression), and telogen (rest), with additional phases of exogen (shedding) and kenogen (transient follicle emptiness) [16]. New cycle initiation occurs through neogen, in which the dermal papilla re-engages follicular stem cells [17]. Cycles occur asynchronously across follicular units and repeat approximately 10–30 times throughout a person’s lifetime [18]. In healthy scalps, normal daily shedding of 100–150 hairs is typically imperceptible, and telogen rates >20% become concerning for pathologic shedding [17–19].

In contrast to androgen-dependent hair growth in regions such as the axillae and groin, androgens can drive progressive miniaturization of genetically susceptible scalp hair follicles, resulting in AGA [20, 21]. This process most commonly affects the frontotemporal scalp, with additional vertex involvement in men and central part widening in women, and is characterized by gradual or abrupt conversion of terminal hairs into finer vellus hairs, accompanied by shortening of the anagen phase [21].

Several mechanisms are implicated in follicular regression. Reduced vascularity around the dermal papilla occurs early in the androgen-driven miniaturization process in AGA, mediated in part by transforming growth factor β signaling that triggers apoptosis of microvascular endothelial cells [22]. Adequate perifollicular vascularization is essential for nutrient delivery and metabolic support required for hair growth and follicular function [23]. Additionally, apoptotic cells during the catagen phase may propagate cell death to adjacent cells; however, this effect is notably excluded near follicular stem cell populations, potentially due to the localized release of pro-survival molecular factors [24]. Dysregulation of these pathways may therefore contribute to the development of hair loss disorders, including AGA.

Minoxidil Mechanism of Action

Minoxidil is widely used to treat AGA and promotes hair growth through multiple complementary mechanisms. Originally developed as an antihypertensive, oral minoxidil was noted to cause hypertrichosis [25], prompting investigation of its utility in hair loss. As a potent vasodilator, the drug may increase the delivery of oxygen and nutrients to hair follicles, and its mechanism in supporting hair growth is likely multifactorial [5].

Importantly, minoxidil is converted by follicular sulfotransferases into its active sulfate form. Once activated, it induces a dose-dependent increase in vascular endothelial growth factor, which is most highly expressed during the anagen phase; this may also enhance vascularization of the dermal papilla [26]. Research demonstrates that minoxidil opens ATP-sensitive potassium (KATP) channels and supports a role for KATP channel modulation in follicular growth, with one study reporting decreased hair growth after tolbutamine-induced KATP channel closure. Moreover, recent work suggests that minoxidil downregulates the dermal papilla androgen receptor and steroid 17-alpha-hydroxylase/17,20-lyase (CYP17A1), an enzyme in the dihydrotestosterone biosynthetic pathway, ultimately decreasing peripheral production of dihydrotestosterone [27]. In addition, there is evidence that minoxidil activates the beta-catenin pathway in the dermal papilla, thereby prolonging the anagen phase [28]. Ultimately, minoxidil appears to promote hair growth through several local mechanisms at the hair follicle: enhancing vascularization, modulating the hormonal environment of the dermal papilla, and extending the anagen phase.

Use and Efficacy of Minoxidil

Minoxidil is used for the treatment of AGA in both topical and oral capacities [29]. Topical minoxidil is one of two FDA-approved medications for male AGA and the only FDA-approved therapy for female AGA [29, 30]. In men, 5% twice daily demonstrates superior efficacy over 2% formulations, whereas studies in women show similar objective hair count outcomes between 2% and 5% when used twice daily [31, 32]. Current dosing recommendations for topical minoxidil differ by sex: in men, 5% is approved for twice daily use, while in women, 2% is approved twice daily and 5% once daily [3, 29].

Topical minoxidil is available primarily as a solution or foam [29]. Though studies comparing concentrations in women with AGA have not demonstrated significant differences in objective hair outcomes, differences in formulation and dosing frequency limit direct comparison [33]. Common adverse effects, including hypertrichosis and scalp irritation, are generally mild, and solution formulations have a higher risk of scalp irritation, possibly due to propylene glycol [34].

Despite proven efficacy and lower risk of systemic side effects compared to oral formulations, topical minoxidil effectiveness is frequently limited by poor adherence [29, 35]. Application burden, scalp irritation, and perceived lack of improvement contribute to discontinuation rates exceeding 80%, with most patients discontinuing treatment within 6 months [35–37].

Low-dose oral minoxidil, typically ≤5 mg daily, has been utilized off-label in the treatment of male and female AGA [29], and the systemic form overcomes multiple topical barriers, offering standardized dosing and elimination of application concerns [35]. Nevertheless, randomized trials have found comparable improvements in hair density and diameter between low-dose oral minoxidil and topical minoxidil in both men and women with AGA [9, 38].

Mechanistic Rationale for Tretinoin as an Adjunct to Topical Minoxidil

As oral minoxidil and 5-alpha-reductase inhibitors carry undesirable side effects of hypertrichosis and sexual dysfunction, respectively, topical minoxidil monotherapy is frequently used for AGA [39, 40]. However, clinical responsiveness is limited by poor long-term adherence to twice-daily application and by enzyme deficits that impair minoxidil activation, with only 40% of patients achieving cosmetically significant hair regrowth [5, 7]. Thus, there is a need to explore adjuvant therapies and combination strategies to improve the effectiveness of topical minoxidil.

One of the most frequently utilized strategies is a combination of minoxidil with topical tretinoin. Tretinoin, also known chemically as all trans retinoic acid (ATRA), is a vitamin A derivative belonging to the retinoid class. It is frequently used to treat acne vulgaris and photoaging [41]. Unlike other keratinolytic agents, the mechanism of tretinoin extends beyond physically loosening keratinocyte cohesion. As a lipophilic molecule capable of traversing cell and nuclear membranes, tretinoin modulates genetic expression to induce broad changes in cellular behavior within the epidermis, dermis, and adnexal structures [42, 43]. Similar to other retinoids, tretinoin signaling is facilitated by retinoic acid receptor (RAR) and retinoid X receptor (RXR) transcription factor families. A conformational shift of RARs upon tretinoin binding allows for heterodimer complex formation with RXR, which then binds DNA and recruits coactivator complexes that modify chromatin structure and activate target gene transcription [44]. This broad transcriptional regulation induced by tretinoin contributes to its proposed multifaceted enhancement of minoxidil efficacy, including enhanced absorption and activation of minoxidil, as well as synergistic cell survival signaling effects on the hair follicle itself.

Stratum Corneum Remodeling and Enhanced Follicular Delivery

One of the primary effects of tretinoin is upregulation of genes responsible for proliferation in the basal keratinocytes, which stimulates a more rapid progression of cells through epithelial layers [45]. Simultaneously, there is a decrease in desmosomal protein expression, reducing corneocyte cohesion and leading to desquamation and stratum corneum thinning [46]. This lowers skin barrier resistance and may enhance penetration of topical agents such as minoxidil [14]. Additionally, tretinoin reduces hyperkeratotic debris and subsequently comedone formation and follicular occlusion [47]. This follicle-opening effect is a plausible mechanism of enhancing minoxidil efficacy, given that minoxidil primarily targets the structures with the hair follicle, such as the dermal papilla and hair bulb [33, 48].

Foundational pharmacokinetic evidence for this increased absorption demonstrated that when 0.05% tretinoin cream was applied before 2% minoxidil, there was approximately a 2.7-fold increase in systemic absorption compared to topical minoxidil alone, versus a 1.3-fold increase when minoxidil was applied with a vehicle control cream [14]. The researchers also found an increase in transepidermal water loss in the tretinoin pre-treatment group, verifying an increased stratum corneum permeability. They reported that decreased corneocyte adhesion was likely responsible for this increased permeability, as the stratum corneum thickness was not different between groups.

Induction of Follicular Sulfotransferase Activity and Minoxidil Activation

While some studies have shown combination therapy to improve hair growth in the general population with AGA, benefits may be more pronounced in patients previously nonresponsive to minoxidil [10]. Because minoxidil is a prodrug that must be activated by sulfotransferase enzymes (SULT1A1) located in the outer root sheath, patients with low sulfotransferase activity are predisposed to poor treatment responses [8, 49]. For these patients, it is especially important to identify agents capable of inducing SULT1A1 expression. Retinoids such as tretinoin modulate RXRs, which are involved in SULT1A1 gene transcription [50]. It was found that three out of seven predicted nonresponders (low SULT1A1 activity, Minoxidil Response Test <0.4) converted to responders after 5 days of once-daily 0.1% topical tretinoin [10]. Notably, there were no statistically significant increases in enzyme activity in the predicted minoxidil responders (normal SULT1A1 activity, Minoxidil Response Test >0.4). Research indicates that co-administering tretinoin can upregulate minoxidil-activating enzymes, which directly addresses a root cause of minoxidil nonresponse in many patients.

Dermal Papilla Survival Signaling and Apoptosis Modulation

Beyond improving delivery and activation of minoxidil, there is evidence that tretinoin also exerts direct, complementary effects on the hair follicle. The hair follicle continuously cycles through phases of growth and regression, patterns which are controlled by a balance of survival signals and apoptosis within the dermal papilla cells [51]. Kwon et al. [52] provided the first molecular evidence that tretinoin modulates these signals to exert synergistic effects on hair growth. The investigators treated cultured human dermal papilla cells, normal human keratinocytes, and human hair follicle organ cultures with ATRA alone, minoxidil alone, or a combination of both. Results demonstrated that the combination therapy enhanced hair shaft elongation significantly more than minoxidil alone. Western blot analysis indicated that this increased growth was mediated by activation of proliferation survival pathways, specifically showing increased phosphorylated ERK and Akt. The combination therapy also regulated apoptosis by increasing the anti-apoptotic Bcl-2/Bax ratio and downregulating the expression of pro-apoptotic markers p53 and p21. Overall, these findings show that combination therapy may be more effective at prolonging dermal papilla cell survival and delaying apoptosis. By preserving these cells, combination therapy acts to reduce follicular miniaturization, the key cellular pathology of AGA, and ultimately may lead to increased hair density.

Translational and Clinical Implications

Given that the burden of twice-daily application is a primary reason for treatment discontinuation in AGA, adding tretinoin to minoxidil has significant implications: the enhanced absorption and activation of minoxidil paired with the synergistic promotion of follicular growth may allow for less frequent dosing regimens without compromising efficacy [15]. It should be noted that while this synergistic effect has primarily been studied with ATRA, which binds all three RAR subtypes, other retinoids may also enhance the effect of minoxidil. However, the activation of RAR-alpha specifically has been shown to promote dermal collagen deposition and downregulate matrix metalloproteinases [53]. This mechanism likely optimizes the structural environment for the hair follicle; therefore, retinoids that do not target RAR-alpha, such as tazarotene and trifarotene, may not provide the same level of benefit in AGA, though this remains to be tested.

Clinical Evidence for Topical Tretinoin with Topical Minoxidil

Randomized Controlled Trials

Clinical efficacy data from RCTs are sparse. Shin et al. [15] conducted a randomized, double-blind, comparative trial in men with AGA (Hamilton-Norwood III-V), designed to test whether a once-daily combined preparation could achieve outcomes comparable to standard twice-daily 5% minoxidil. Thirty-one men were randomized to either conventional 5% minoxidil twice daily or 5% minoxidil + 0.01% tretinoin applied once nightly plus a morning vehicle placebo; 29 completed 18 weeks of treatment. Objective macrophotographic measures demonstrated significant within-group increases in total hair count and non-vellus hair count in both arms, without statistically significant between-group differences across assessed parameters (including hair counts, anagen ratio, growth rate, and mean diameter). Subjective global assessments by patients and investigators were likewise similar between groups. Adverse events (pruritus/irritation) occurred at comparable frequencies and were generally mild and self-limited, suggesting short-term tolerability in this setting. This trial suggests that adding low-concentration tretinoin to 5% topical minoxidil may permit a reduced application frequency (once daily) while maintaining short-term efficacy comparable to the conventional twice-daily 5% minoxidil regimen.

However, the overall randomized evidence base remains limited and should be interpreted cautiously. More definitive conclusions require larger, longer-duration randomized trials that include clinically meaningful endpoints, broader populations (including women and diverse scalp phenotypes), and systematic safety monitoring, particularly of irritation/dermatitis and any markers of increased systemic exposure that could be theoretically amplified by barrier disruption. Given that real-world persistence with topical minoxidil is poor, future trials should also prospectively measure adherence and attrition, since any efficacy advantage may be negated if combination regimens increase irritation or application burden and thereby worsen long-term compliance.

Real-World Data and Case Series

Beyond randomized trials, published real-world experience with topical minoxidil plus topical tretinoin consists mainly of small pilot cohorts and case reports spanning AGA and selected congenital hair disorders. In an early clinical pilot series of 56 normotensive adults with AGA treated in several small studies (1983–1986), patients applied 0.025% tretinoin solution alone (n = 12) or in combination with 0.5% minoxidil (n = 36) twice daily; small comparator groups received vehicle (n = 5) or 0.5% minoxidil alone (n = 3) [12]. The combination arm showed terminal hair improvement in roughly two-thirds of patients, whereas tretinoin monotherapy produced measurable but usually modest regrowth in just over half; the minoxidil-alone and vehicle groups did not demonstrate meaningful terminal regrowth in this small experience. Notably, responses ranged from vellus/lanugo changes to marked terminal regrowth, including an individual with long-standing extensive alopecia who had striking improvement with tretinoin alone over 18 months, suggesting that a subset of patients may respond even without minoxidil, albeit unpredictably. Practical challenges were also evident: 2 patients discontinued therapy due to sensitivity consistent with irritant or contact dermatitis, underscoring the main real-world barrier to use: tolerability and adherence. Alcohol/pro-pylene-glycol vehicles and twice-daily application schedules were identified as the main culprits for these challenges. A key limitation is that this early experience used 0.5% minoxidil, substantially lower than the 2% and 5% formulations used in contemporary practice, so efficacy and tolerability findings may not be directly generalizable to modern regimens.

Case reports extend the combination concept to congenital hypotrichosis syndromes, where follicle maturation is reduced. In a child with Clouston syndrome (hidrotic ectodermal dysplasia), a regimen of 2% minoxidil solution (1 mL twice daily) with 0.05% tretinoin cream applied once daily approximately 1 h before minoxidil (plus oral biotin) was associated with a clinically apparent increase in scalp hair density over 6 months, with vellus hairs reportedly transitioning toward more terminal-appearing growth [54]. Similarly, in two pediatric cases of congenital woolly hair with diffuse short, tightly curled hair and low density since birth, daily topical minoxidil (3% gel) and tretinoin (0.025%) were used alongside an oral vitamin D analog (alfacalcidol 0.25 µg/day). Both patients demonstrated improved hair thickness and density on digital videodermatoscopy (Folliscope, Anagen Inc., Seoul, South Korea) after 5 months, with continued clinical improvement reported over seven to 8 months of follow-up [55]. Reported challenges again centered on tolerability, with transient irritation attributable to tretinoin in one case. These cases also highlight a real-world confounder in interpreting benefit: combination regimens often include additional systemic agents, making the isolated contribution of tretinoin difficult to quantify.

Finally, a short exploratory clinical study provides mechanistic support for why tretinoin has been investigated as an adjunct to topical minoxidil. In a previously described study of 20 adults with AGA, 5 days of topical 0.1% tretinoin applied to a defined scalp target area did not significantly change mean SULT1A1 activity across the overall cohort. However, the subgroup with low baseline follicular sulfotransferase activity (“predicted nonresponders”), tretinoin increased enzymatic activity and converted 43% to “predicted responders” after only 5 days [10]. The direct applicability of this stratified approach is currently limited because SULT1A1 testing is not routinely clinically available, and therefore baseline identification of likely nonresponders is generally not feasible in everyday practice. Nevertheless, these findings support considering tretinoin as an adjunct in patients with inadequate clinical response to topical minoxidil, while emphasizing the need to balance any potentiation strategy against irritation-driven nonadherence and the theoretical possibility of increased systemic exposure with barrier disruption. An overview of research investigating the combination is provided in Table 1.

Table 1.

Overview of studies comparing topical minoxidil monotherapy with topical tretinoin and topical minoxidil combination therapy

Evidence	Study	Results	Side effects
PK/barrier	Ferry et al. [14] (1990); randomized crossover; n = 19; 20 days	Minoxidil absorption ↑ ∼3× with tretinoin vs. minoxidil alone; vehicle ↑ ∼1.3×	TEWL ↑ with tretinoin; no SC thickness change reported (biopsy)
Clinical pilot	Bazzano et al. [12] (1986); small pilot cohorts of patients with AGA; n = 56	Combo (0.5% MIN + 0.025% TRET) showed higher terminal regrowth rates than small MIN-alone/vehicle groups	Irritation/possible contact dermatitis led to 2 exclusions (TRET sensitivity)
RCT (clinical)	Shin et al.[15] (2007); DB-RCT; AGA; ∼18 week; 5% MIN BID vs. 5% MIN + 0.01% TRET QHS	Both arms improved; no significant added benefit with TRET vs. standard 5% MIN BID	Pruritus/irritation similar; folliculitis reported in control arm
Mechanistic	Sharma et al. [10] (2019); AGA; n = 20; TRET 0.1% daily ×5 day; outcome = follicular ST activity	ST activity ↑ in predicted nonresponders; 43% converted to predicted responders	No AEs reported
Case report	Melkote et al. [54] (2009); Clouston; child; MIN 2% BID + TRET 0.05% QD (+biotin)	Marked clinical improvement in density/terminalization (confounded regimen)	Mild forehead hypertrichosis
Case series	Choi et al. [55] (2016); 2 children; woolly hair; MIN 3% gel + TRET 0.025% daily (+alfacalcidol)	Thickness and density increased at ∼5 months (confounded regimen)	Minor transient irritation in 1 case

AGA, androgenetic alopecia; AE, adverse event; BID, twice daily; DB, double-blind; MIN, minoxidil; PK, pharmacokinetic; QD, once daily; QHS, nightly; RCT, randomized controlled trial; SC, stratum corneum; ST, sulfotransferase; TEWL, transepidermal water loss.

Italicized text indicates positive results, and bold text indicates negative results.

Safety and Tolerability of Combined Topical Tretinoin and Minoxidil

As both tretinoin and minoxidil carry individual risks, it is important to carefully consider the safety profile of combination therapy before recommending long-term use. This assessment includes evaluating local cutaneous tolerability, systemic absorption risks, and reproductive safety.

Local Cutaneous Adverse Events

The primary adverse effects associated with topical tretinoin are local, cutaneous irritability, often referred to as the “retinoid reaction.” These symptoms, which include redness, peeling, itching, and burning or stinging, are typically dose-dependent and peak within the first few weeks before subsiding [44]. Notably, rates of irritation for tretinoin and topical minoxidil combined therapy compared to topical minoxidil monotherapy were found to be similar in one RCT [15], and scalp irritation is also a common reason for discontinuing topical minoxidil [36]. This reaction was previously considered an allergic reaction to minoxidil itself. However, research has identified propylene glycol, a hydrophilic vehicle used in some formulations to increase water solubility, as the more likely cause [33, 34, 56, 57]. Propylene glycol-free formulations, including novel hydrogel and nanotechnology-based cubosome vehicles, display lower rates of intolerance and have not exhibited inferior outcomes [33, 58, 59]. Another adverse reaction seen in 4% of patients taking topical minoxidil is facial hypertrichosis, which presents with unwanted fine hair growth on the cheeks, forehead, chin, and near the lips [60].

Lack of efficacy, complex regimens, and side effects have been cited as the most common hurdles to adherence for both long-term topical retinoid and minoxidil therapies [61–63]. While combining tretinoin with minoxidil may improve efficacy and simplify regimens by reducing the need for twice-daily therapy, it may increase the risk of local irritation and dryness. For retinoid-minoxidil combined regimens, it is especially important to consider strategies to reduce topical reactions, especially in patients with textured hair prone to dryness and breakage. Compounded formulations often utilize low-potency corticosteroids and oil or ointment-based vehicles, though they are typically more expensive than over-the-counter options [64]. However, while the inclusion of steroids reduces inflammation and moisture loss, the risk of atrophy limits their long-term viability.

Systemic Absorption and Cardiovascular Risks

In the systemic circulation, minoxidil functions as a potent vasodilator and carries a risk of tachycardia, edema, and hypotension when levels exceed 20 ng/mL [29]. These effects are rarely seen in patients taking topical minoxidil, as the 5% solution produces mean serum levels of 1.2 ng/mL [65]. Even with concomitant tretinoin, serum minoxidil concentrations are unlikely to exceed 20 ng/mL, as quantitative data indicate that topical tretinoin increases absorption by less than threefold [14]. Clinical trials have not demonstrated an increase in systemic cardiovascular events in patients taking combined topical 0.1% tretinoin and 5% minoxidil [15]. Nonetheless, patients with a history of heart disease should use shared decision-making with their physician before beginning topical therapy, and patients should stop use if they develop concerning symptoms, including chest pain, dizziness, rapid heartbeat, sudden weight gain, or swelling of the hands or feet.

Reproductive Safety

A critical systemic risk for both medications concerns women of childbearing potential. Retinoids are known to be teratogenic, with oral agents such as isotretinoin causing a pattern of birth defects, including craniofacial, cardiac, thymic, and CNS malformations, by disrupting crucial RAR signaling during development [66, 67]. Topical retinoid use has not shown a consistent pattern of teratogenicity, but theoretical concerns remain. While classification systems have changed, tretinoin was formerly classified by the FDA as pregnancy category C, indicating that animal studies have shown adverse effects, and human data are lacking.

Minoxidil was also formerly classified as pregnancy category C, and experts currently advise against using either oral or topical formulations during this period. There have been documented reports of fetal cardiovascular malformations and hypertrichosis following exposure to both oral and topical minoxidil during pregnancy [68–70]. Given these risks and the nonurgent nature of AGA, both topical minoxidil and tretinoin should be avoided during pregnancy. Additionally, women of childbearing age should be counseled on the risks and advised to use contraception while on therapy. If patients are inadvertently exposed to either agent, they can be reassured that the absolute risk of fetal defects is low, although fetal anatomy scans may be offered for confirmation.

Results from Social Media Analysis of Topical Tretinoin and Topical Minoxidil

For the social media analysis, we evaluated 71 high-impact posts (20 each from Google and TikTok, 18 from Instagram, and 13 from Reddit). All referenced both topical minoxidil and topical tretinoin, and of 56 posts where the creator’s gender was made apparent, 22 (39.3%) were male. Engagement was high on Instagram and TikTok (median [IQR] views: 208,500 [64,800–693,500] and 156,000 [78,500–304,725], respectively), while Reddit posts had lower interaction metrics (likes: 11 [6–21]; comments: 25 [10–40]).

Across all platforms, most posts (43 [60.6%]) were informational, and some were from personal experience (23 [32.4%]) or promotional (7 [9.9%]). The vast majority claimed hair regrowth in general (68 [95.8%]), with a minority mentioning thickened hair (11 [15.5%]) and reduced shedding (11 [15.5%]), and even fewer reporting increased shedding (7 [9.9%]). Sentiment was largely favorable, with most posts coded as positive overall (43 [60.6%]) and positive specifically regarding the tretinoin-minoxidil interaction (48 [67.6%]). Negative posts were rare, with rates <5% for each category. Tolerability concerns were frequent and often framed as a barrier to treatment adherence: Several posts reported irritation (29 [40.8%]); mentions of erythema (16 [22.5%]), pruritus (13 [18.3%]) and burning (10 [14.1%]) were also prevalent.

Among posts with creator type specified, 30 of 69 (43.5%) were authored by physicians and 39 (56.5%) by nonphysicians. Among physician posts, only 5 (20%) included a citation. Content framing differed by creator type: Physicians were predominantly informational (26/30 [86.7%]), whereas nonphysicians more often shared personal experience (21 [53.8%]; p < 0.001). Sentiment and mentions of tolerability symptoms were similar between groups.

These real-world perceptions align with themes in the published literature. Social media posts are largely positive regarding the results of combination therapy, in comparison to the use of topical minoxidil alone. However, results support evidence from clinical studies, suggesting that any potential benefit of topical tretinoin, when used concomitantly with topical minoxidil, should be balanced against side effects, including irritation and erythema, and adherence limitations.

Clinical Recommendations

Despite these results, evidence supports minoxidil monotherapy and the use of anti-androgens, such as finasteride, dutasteride, or spironolactone, before consideration of topical tretinoin [65]. Aside from topical minoxidil, oral finasteride remains the only other FDA-approved medication for AGA, though its approval is limited to men and its use in women is off-label [65, 71]. Notably, no comparative studies have evaluated combination topical minoxidil and tretinoin therapy against procedural interventions such as platelet-rich plasma, non-ablative fractional lasers, or hair transplantation. While procedural modalities may be effective, they often carry a substantial financial burden. Therefore, a trial of topical tretinoin and topical minoxidil is a reasonable alternative for clinicians to discuss before pursuing more invasive options, especially with patients who cannot tolerate systemic options.

Although topical tretinoin is not typically considered a first-line therapy, it may be beneficial for patients who are partial responders or nonresponders to topical minoxidil or those who cannot take oral minoxidil [10, 29]. This option is particularly relevant for patients who prefer to remain on topical therapies and wish to minimize or avoid potential adverse effects associated with oral modalities. However, patients should be counseled that limited studies exist on this approach, and responses may vary based on individual factors and adherence.

In terms of efficacy, the ideal timing of tretinoin relative to minoxidil remains unclear. Sequential application, with tretinoin applied first, could theoretically enhance minoxidil penetration and efficacy [14]; however, this strategy has not been directly compared with synchronous administration, such as with compounded formulations. Therefore, regimen selection should prioritize adherence, which may favor simultaneous therapy, while also considering cost, availability, and patient preference. Non-compounded approaches potentially increase accessibility, but add application burden and, if using a sequential regimen, require patient education on timing. Compounded formulations simplify administration to a single step and allow for potential customization to mitigate local irritation, though they may have lower availability and can require a compounding fee. The optimal choice depends on individual patient factors, such as tolerability and application preference. Further studies are needed to define the optimal timing strategy and determine whether sequential tretinoin application meaningfully improves minoxidil absorption or clinical efficacy.

Major Open Questions

While this dual therapy has promise for treating AGA, there is an absence of robust data demonstrating clinical benefit. Heterogeneity in outcome measures is an established barrier in studies comparing the efficacy of AGA treatment modalities, and this is a critical gap in existing combination tretinoin-minoxidil literature [30, 72]. In their RCTs, Shin et al. [15] evaluated hair count, non-vellus hair count, and hair diameter using macrophotographic image analysis rather than standardized phototrichogram protocols, which are considered the gold standard for quantifying treatment response in alopecia research. Underutilization of global photography and patient-reported outcome measures in minoxidil-tretinoin combination studies further limits comparative efficacy assessments and the creation of evidence-based clinical recommendations.

Additionally, the lack of long-term follow-up data in tretinoin-minoxidil studies limits understanding of sustained efficacy and durability of treatment response. In the head-to-head RCT, follow-up was limited to 18 weeks [15], and in the study reporting that tretinoin application converted 43% of subjects from minoxidil nonresponders to responders, the observation period was 5 days [10]. Thus, there is limited interpretation of these results with respect to long-term hair regrowth. Moreover, discussion of topical minoxidil and tretinoin therapy efficacy is absent from scoping reviews, making comparison to other treatment modalities difficult. In a recent meta-analysis examining the efficacy of minoxidil in combination with other pharmacological agents for the treatment of AGA, ten adjunctive therapies were discussed; tretinoin, however, was not included, suggesting insufficient high-quality evidence [73].

Future research should prioritize large-scale, long-term RCTs comparing combination topical minoxidil and tretinoin therapy to minoxidil monotherapy regimens using standardized outcome measures. In addition, there is a paucity of research exploring whether topical tretinoin can augment the efficacy of oral minoxidil via the same follicular sulfotransferase mechanism established for topical minoxidil. While there is extensive literature on oral minoxidil combination strategies in AGA treatment, none of these reviews or consensus statements mention combining oral minoxidil with topical tretinoin [10, 29, 74, 75]. This represents an unexplored area in current clinical literature that should be addressed in future mechanistic and translational studies.

Conclusion

This review demonstrates that topical tretinoin has a mechanistic link to increasing minoxidil activation, particularly through increased skin permeability and the follicular sulfotransferase enzyme. Given the ongoing need for effective adjunctive and combination therapies for AGA, the addition of topical tretinoin to topical minoxidil presents as an interesting option to further explore. Although evidence suggests that topical tretinoin may increase the efficacy of topical minoxidil in some patients, existing clinical data remain equivocal as to whether combination therapy truly leads to superior outcomes compared to topical minoxidil monotherapy [12, 15].

The potential benefit of adding topical tretinoin to topical minoxidil must also be weighed against possible side effects such as scalp irritation or pruritus. As such, tolerability is a potential limiting factor [15], and future studies should assess the long-term associated risk. Well-designed clinical trials are warranted to further characterize the efficacy of topical tretinoin for the treatment of AGA and determine optimal formulations and dosing strategies.

Conflict of Interest Statement

Drs. Shapiro and Lo Sicco are prior investigators for Pfizer and Regenlab. Dr. Lo Sicco is a consultant for Pfizer, Lilly, Ro, Priovant, Veradermics, and Aquis. Dr. Shapiro is a consultant or on the medical advisory board for Veradermics, 30 Madison, Pfizer, Lilly, Sun Pharma, Abbvie, Cassiopea, DS Laboratories, and Eirion. Kristen I. Lo Sicco was a member of the journal’s Editorial Board at the time of submission. The other authors have no conflicts of interest to declare.

Funding Sources

This study was not supported by any sponsor or funder.

Author Contributions

Conceptualization and supervision: K.I.L.; writing (original draft): D.M., A.S., I.Z., K.M., A.B., C.T., L.G.G., and J.P.; writing (review and editing): J.S. and K.I.L.; and visualization: D.M. and J.P.

Funding Statement

This study was not supported by any sponsor or funder.